Atlas Trials

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

Clinical trial NCT02867813 · COMPLETED

Trial details

NCT number
NCT02867813
Sponsor
Amgen
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Dyslipidemia
Start date
2016-09-02
Primary completion
2022-03-21
Enrollment
5035

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.